Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 93 Neoplasm Metastasis 6 Prostatic Neoplasms, Castration-Resistant 3 Prostatic Diseases 2 Non-metastatic Castration-resistant Prostate Cancer 2 Neoplasms 2 Genital Diseases, Male 2 Urogenital Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Sleep Initiation and Maintenance Disorders 1 Salivary Gland Neoplasms 1 Prostate Cancer With ≤10 Bone Metastases 1 Prostate Cancer Metastatic Disease 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Patient Preference 1 Non-metastatic Prostate Cancer 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms by Site 1 Neoadjuvant Therapy 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Low Risk Prostate Cancer 1 High-Risk and Oligometastatic Prostate Cancer 1

Interventions

Cisplatin 19 Docetaxel 17 Cetuximab 12 Carboplatin 12 Radiotherapy 11 Magnetic Resonance Spectroscopy 10 Biopsy 10 pembrolizumab 9 Paclitaxel 9 Radiotherapy, Intensity-Modulated 8 Immunohistochemistry 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Gemcitabine 7 Chemotherapy, Adjuvant 7 Specimen Handling 6 Radiotherapy, Conformal 5 Radiosurgery 5 Gene Expression Profiling 5 Fluorodeoxyglucose F18 5 Capecitabine 5 Vorinostat 4 Taxes 4 Sorafenib 4 Polymerase Chain Reaction 4 Nivolumab 4 Bevacizumab 4 trastuzumab deruxtecan 3 sargramostim 3 bicalutamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × apalutamide × Clear all

NCT04325828 2026-05-08

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡